TY-JOURTI-InstitutiveMRTF激活为PirfenidoneJF-Eur Respir JOO-Eur Respir JDO-10.183/13993003.00604-2022VL-61IS-4SP-2200604AU-MaAU-Vander HeidenAU-UTtarwar-AU-Xia-YangAU-N'Diaye/Elsa-NoahAU-LaCanna/RyanAU-Caplazi/PatrickAU-Gierke/SarahAU-Moffat/JohnAU-Wolters/PaulJAU-Ding,NingY1-2023/04/01UR-//www.qdcxjkg.com/content/61/4/220064.abstractN2-IPFPirfenidone(PFD)作为第一批经核准的IPF药物,显著减慢肺功能下降,而基础反fibrotic机制仍然难以实现。Methods-Service并显示PFD抑制初级人类肺部浮点数(半最大抑制富集度50-150M,最大抑制量>90%,最大富集度 < 100mPFD似乎通过促进MRTF和间接行为交互作用来产生抑制效果PFD处理过的IPF肺比naitFT肺小得多MRTF激活